肺癌肺叶切除术:开放、胸腔镜与机器人入路的系统综述与网状Meta分析
该研究通过贝叶斯网状Meta分析比较开放、胸腔镜(VATS)与机器人肺叶切除术的围术期及肿瘤学结局,纳入34项研究共183,426例患者。与开放手术相比,VATS和机器人手术的30天死亡率、肺部并发症及总体并发症显著降低;VATS的淋巴结清扫数目少于开放和机器人手术,但阳性切缘和5年总生存率三组相似。微创技术可能改善结局,在可行时应鼓励采用VATS或机器人肺叶切除术。
要点
- 与开放肺叶切除术相比,VATS和机器人手术的30天死亡率、肺部并发症和总体并发症显著降低。
- VATS的淋巴结清扫总数和站数显著少于开放和机器人手术,但阳性切缘和5年总生存率三组相似。
- 微创入路的术中出血、术后输血、住院时间和30天再入院显著减少。
核心结论
- 与开放肺叶切除术相比,VATS和机器人肺叶切除术似乎更安全,30天死亡率、肺部并发症和总体并发症降低,且肿瘤学结局和5年总生存率相当。
- 微创技术可能改善结局,在可行时应鼓励外科医生采用VATS或机器人肺叶切除术治疗肺癌。
研究设计与样本
- 系统综述与完全贝叶斯网状Meta分析,检索PubMed、EMBASE和Web of Science数据库。
- 共纳入34项研究、183,426例患者;开放肺叶切除术88,865例(48.4%),VATS肺叶切除术79,171例(43.2%),机器人肺叶切除术15,390例(8.4%)。
主要发现
- 与开放肺叶切除术相比,VATS和机器人肺叶切除术的30天死亡率风险比分别为0.53(95%可信区间0.40-0.66)和0.51(95%可信区间0.36-0.71)。
- 与开放肺叶切除术相比,VATS和机器人肺叶切除术的肺部并发症风险比分别为0.70(95%可信区间0.51-0.92)和0.69(95%可信区间0.51-0.88)。
- 与开放肺叶切除术相比,VATS和机器人肺叶切除术的总体并发症风险比分别为0.77(95%可信区间0.68-0.85)和0.79(95%可信区间0.67-0.91)。
- 与VATS肺叶切除术相比,开放和机器人肺叶切除术的淋巴结清扫总数平均差异分别为1.46(95%可信区间0.30-2.64)和2.18(95%可信区间0.52-3.92),淋巴结站数平均差异分别为0.37(95%可信区间0.08-0.65)和0.93(95%可信区间0.47-1.40)。
- 阳性切缘和5年总生存率在各治疗间相似;微创入路的术中出血、术后输血、住院时间和30天再入院显著减少。
临床怎么用
- 在可行的情况下,应优先考虑VATS或机器人肺叶切除术以降低30天死亡率、肺部并发症和总体并发症。
- 选择VATS时需注意其淋巴结清扫数目可能少于开放或机器人手术,应确保足够的淋巴结采样或清扫。
- 微创入路可减少术中出血、术后输血、住院时间和30天再入院,有利于围术期恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although minimally invasive lobectomy has gained worldwide interest, there has been debate on perioperative and oncological outcomes. The purpose of this study was to compare outcomes among open lobectomy, video-assisted thoracic surgery lobectomy, and robotic lobectomy. METHODS: PubMed, EMBASE, and Web of Science databases were consulted. A fully Bayesian network meta-analysis was performed. RESULTS: Thirty-four studies (183,426 patients) were included; 88,865 (48.4%) underwent open lobectomy, 79,171 (43.2%) video-assisted thoracic surgery lobectomy, and 15,390 (8.4%) robotic lobectomy. Compared with open lobectomy, video-assisted thoracic surgery, lobectomy and robotic lobectomy had significantly reduced 30-day mortality (risk ratio = 0.53; 95% credible intervals, 0.40-0.66 and risk ratio = 0.51; 95% credible intervals, 0.36-0.71), pulmonary complications (risk ratio = 0.70; 95% credible intervals, 0.51-0.92 and risk ratio = 0.69; 95% credible intervals, 0.51-0.88), and overall complications (risk ratio = 0.77; 95% credible intervals, 0.68-0.85 and risk ratio = 0.79; 95% credible intervals, 0.67-0.91). Compared with video-assisted thoracic surgery lobectomy, open lobectomy, and robotic lobectomy had a significantly higher total number of harvested lymph nodes (mean difference = 1.46; 95% credible intervals, 0.30, 2.64 and mean difference = 2.18; 95% credible intervals, 0.52-3.92) and lymph nodes stations (mean difference = 0.37; 95% credible intervals, 0.08-0.65 and mean difference = 0.93; 95% credible intervals, 0.47-1.40). Positive resection margin and 5-year overall survival were similar across treatments. Intraoperative blood loss, postoperative transfusion, hospital length of stay, and 30-day readmission were significantly reduced for minimally invasive approaches. CONCLUSION: Compared with open lobectomy, video-assisted thoracic surgery lobectomy, and robotic lobectomy seem safer with reduced 30-day mortality, pulmonary, and overall complications with equivalent oncologic outcomes and 5-year overall survival. Minimally invasive techniques may improve outcomes and surgeons should be encouraged, when feasible, to adopt video-assisted thoracic surgery lobectomy, or robotic lobectomy in the treatment of lung cancer.
引用
- Aiolfi A, Nosotti M, Micheletto G, et al. Pulmonary lobectomy for cancer: Systematic review and network meta-analysis comparing open, video-assisted thoracic surgery, and robotic approach. Surgery. 2020. PMID: 33097244. doi:10.1016/j.surg.2020.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。